Preliminary results of a multicenter dosimetry, efficacy and safety study with iodine-131 tositumomab in treatment of non-Hodgkin's lymphoma (NHL)

被引：0
|
作者：
Kostakoglu, L
Goldsmith, SJ
Buchegger, F
Lewington, V
Leonard, JP
Illidge, T
Ketterer, N
Kovacsovics, T
Valente, N
Bischof-Delaloye, A
机构：
[1] New York Presbyterian Weill Cornell Med Ctr, New York, NY USA
[2] Univ Lausanne Hosp, Lausanne, Switzerland
[3] Univ Hosp Geneva, Geneva, Switzerland
[4] Royal S Hants Hosp, Southampton SO9 4PE, Hants, England
[5] Corixa Corp, S San Francisco, CA USA
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE | 2001年 / 28卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OS73
引用
收藏
页码：979 / 979
页数：1
相关论文
共 50 条
  • [1] Iodine-131 tositumomab for non-Hodgkin's lymphoma (NHL) patients who progressed after treatment with rituximab: Results of a multicenter phase II study.
    Horning, SJ
    Lucas, JB
    Younes, A
    Podoloff, D
    Jain, V
    Kroll, S
    Stagg, R
    Nadeau, K
    Tidmarsh, G
    BLOOD, 2000, 96 (11) : 508A - 508A
  • [2] Dosimetry of iodine I 131 tositumomab in previously untreated patients with non-Hodgkin's lymphoma (NHL).
    Zasadny, KR
    Rommelfanger, SG
    Regan, DD
    McCullough, NT
    Kroll, S
    Kaminski, MS
    Wahl, RL
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 82P - 83P
  • [3] Update on the rational use of tositumomab and iodine-131 tositumomab radioimmunotherapy for the treatment of non-Hodgkin's lymphoma
    Burdick, Michael J.
    Macklis, Roger M.
    ONCOTARGETS AND THERAPY, 2009, 2 : 229 - 242
  • [4] Safety and Efficacy of I(131) Tositumomab in the Treatment of non-Hodgkin's Lymphoma
    Illidge, Tim
    Ivanov, Andrei
    Du, Yong
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 621 - 631
  • [5] Radioimmunotherapy with tositumomab and iodine-131 tositumomab for low-grade non-hodgkin lymphoma: Nursing implications
    Estes, JM
    Clapp, KJ
    ONCOLOGY NURSING FORUM, 2004, 31 (06) : 1119 - 1126
  • [6] Tositumomab and iodine I 131 tositumomab: Efficacy and safety in 141 patients (pts) with previously untreated low-grade (LG) non-Hodgkin's lymphoma (NHL).
    Kaminski, MS
    Coleman, M
    Link, BK
    Wahl, RL
    Goldsmith, SJ
    Kostakoglu, L
    Leonard, JP
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 575S - 575S
  • [7] Bexxar™ (Iodine-131 tositumomab) radio immunotherapy for patients with B-cell non-Hodgkin's lymphoma
    Micallef, I
    Radford, J
    Britten, K
    Owen, S
    Deakin, D
    Jan, H
    Foley, R
    Barlow, R
    Carrington, B
    Lawrance, J
    Vinnicombe, S
    Harris, M
    Norton, A
    Lister, A
    Rohatiner, A
    BRITISH JOURNAL OF CANCER, 2000, 83 : 16 - 16
  • [8] Efficacy and safety of Bexxar® (tositumomab and iodine I 131 tositumomab) in obese patients with low-grade non-Hodgkin's lymphoma.
    Wahl, R
    Goldsmith, SJ
    Zasadny, KR
    Alavi, A
    Divgi, C
    Hankins, J
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 415P - 415P
  • [9] Cost-effectiveness of tositumomab and iodine I-131 tositumomab (Bexxar therapeutic regimen (BTR)), in treatment of non-Hodgkin lymphoma (NHL)
    Flowers, C. R.
    Sambrook, J. C.
    Briggs, A.
    Osenenko, K.
    Wang, H.
    Dalal, M. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] Sequential administration of chemotherapy followed by radioimmunotherapy with Iodine-131-Tositumomab in untreated non-Hodgkin's lymphoma (NHL)
    Kostakoglu, L
    Goldsmith, SJ
    Vallabhajosula, S
    Coleman, M
    Morris, A
    Link, BK
    Kaminski, MS
    Nadeau, K
    Valente, N
    Leonard, JP
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (08): : 981 - 981
12345